Skip to main content
SpringerLink
Log in

Has the NHS been limiting access to high priced drugs?

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. the British Society of Gastroenterology, the British Association for the study of the Liver, the British Viral Hepatology Group, and the Royal College of Pathologists

References

  1. Gornall J, et al. A pill too hard to swallow: how the NHS is limiting access to high priced drugs. BMJ : 27 Jul 2016. Available from: URL: http://dx.doi.org/10.1136/bmj.i4117.

  2. Roy V, et al. Betting on hepatitis C: how financial speculation in drug development influences access to medicines. Internet Document : 27 Jul 2016. Available from: URL: http://dx.doi.org/10.1136/bmj.i3718.

  3. Mazzucato M. High cost of new drugs. Internet Document : 27 Jul 2016. Available from: URL: http://dx.doi.org/10.1136/bmj.i4136.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Has the NHS been limiting access to high priced drugs?. PharmacoEcon Outcomes News 759, 4–5 (2016). https://doi.org/10.1007/s40274-016-3269-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3269-9

Search

Navigation